Additionally, recent studies have revealed that breast cancer cells lacking BRCA1 and SMARCAL1 exhibit resistance to PARP inhibitors and cisplatin, which is accompanied by RF stabilization but does not result in HR restoration [86, 87]. This evidence concerns the gene PARP1 and breast cancer.